|
03.05.2024 19:48:16
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 3 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
| Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 900.05 | 178 shares | |||||
| d) | Aggregated information
| 178 shares DKK 160,208.90 | ||||
| e) | Date of the transaction | 2024-05-02 | ||||
| f) | Place of the transaction | AQUIS EXCHANGE EUROPE AUCTION ON DEMAND (AOD) | ||||
| Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 900.74 | 10,128 shares | |||||
| d) | Aggregated information
| 10,128 shares DKK 9,122,689.30 | ||||
| e) | Date of the transaction | 2024-05-02 | ||||
| f) | Place of the transaction | AQUIS EXCHANGE EUROPE NON DISPLAY ORDER BOOK (NDOB) | ||||
| Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 900.17 | 2,253 shares | |||||
| d) | Aggregated information
| 2,253 shares DKK 2,028,089.70 | ||||
| e) | Date of the transaction | 2024-05-02 | ||||
| f) | Place of the transaction | AQUIS EXCHANGE EUROPE | ||||
| Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 900.10 | 18,153 shares | |||||
| d) | Aggregated information
| 18,153 shares DKK 16,339,540.90 | ||||
| e) | Date of the transaction | 2024-05-02 | ||||
| f) | Place of the transaction | CBOE EUROPE - DXE ORDER BOOKS (NL) | ||||
| Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 900.14 | 2,800 shares | |||||
| d) | Aggregated information
| 2,800 shares DKK 2,520,380.90 | ||||
| e) | Date of the transaction | 2024-05-02 | ||||
| f) | Place of the transaction | TURQUOISE EUROPE | ||||
| Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 900.00 | 10,437 shares | |||||
| d) | Aggregated information
| 10,437 shares DKK 9,393,300.00 | ||||
| e) | Date of the transaction | 2024-05-02 | ||||
| f) | Place of the transaction | UBS EUROPE SE | ||||
| Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 912.15 | 11,051 shares | |||||
| d) | Aggregated information
| 11,051 shares DKK 10,080,130.60 | ||||
| e) | Date of the transaction | 2024-05-02 | ||||
| f) | Place of the transaction | NASDAQ COPENHAGEN A/S | ||||
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
| Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com | Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
| David Heiberg Landsted
+45 3077 6915 dhel@novonordisk.com | Mark Joseph Root (US)
+1 848 213 3219 mjhr@novonordisk.com |
| Sina Meyer +45 3079 6656 azey@novonordisk.com |
Company announcement No 36 / 2024
Attachment
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novo Nordiskmehr Nachrichten
|
09:30 |
Anleger in Europa halten sich zurück: STOXX 50 präsentiert sich zum Start leichter (finanzen.at) | |
|
12.12.24 |
STOXX 50 aktuell: STOXX 50 zum Handelsende schwächer (finanzen.at) | |
|
12.12.24 |
STOXX 50-Handel aktuell: STOXX 50-Anleger greifen nachmittags zu (finanzen.at) | |
|
12.12.24 |
Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events (GlobeNewswire) | |
|
12.12.24 |
Handel in Europa: STOXX 50 verliert am Mittag (finanzen.at) | |
|
12.12.24 |
Börsianer warten auf Impulse: STOXX 50 beginnt die Donnerstagssitzung kaum verändert (finanzen.at) | |
|
11.12.24 |
Börse Europa: STOXX 50 beendet den Mittwochshandel im Plus (finanzen.at) | |
|
11.12.24 |
Börse Europa: STOXX 50 zeigt sich nachmittags fester (finanzen.at) |
Analysen zu Novo Nordiskmehr Analysen
| 12.12.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 10.12.24 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 09.12.24 | Novo Nordisk Neutral | UBS AG | |
| 09.12.24 | Novo Nordisk Underperform | Bernstein Research | |
| 04.12.24 | Novo Nordisk Underperform | Bernstein Research |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.